Bafna Pharmaceuticals: Should You Buy, Hold, or Sell Right Now?
- September 8, 2026
- Posted by: Lakshit Sharma
- Category: Market
Bafna Pharmaceuticals share price Rs 307.75 (NSE), up nearly 2% today, near its 52-week high. 52-week range Rs 94.77 to Rs 318.50. Current-quarter data was not consistently available.
Quick Answer
Bafna Pharmaceuticals Ltd share price is trading around Rs 308, up nearly 2 percent today, close to its 52-week high of Rs 318.50 and more than triple its 52-week low of Rs 94.77. Despite this dramatic stock price appreciation over the past year, current-quarter and recent annual financial data was not consistently available across public sources at the time of writing, with the most recently confirmed disclosures dating back several years. The stock trades at a rich 91.95 times earnings against the pharmaceutical sector average near 50.8 times based on available trailing data, though this figure should be read with real caution given the significant data gap between the confirmed financials and the current dramatic price level.
Bafna Pharmaceuticals share price is up nearly 2 percent today, trading around Rs 308 on the NSE, close to its 52-week high of Rs 318.50, more than triple its 52-week low of Rs 94.77. Given the very significant gap between this dramatic price appreciation and the limited current financial data available, this article presents what is known plainly before laying out a careful, cautious view.
This Bafna Pharmaceuticals overview walks through the available valuation data, the significant data limitations relative to the dramatic price move, and the technical setup, using figures sourced from public filings.
Click Here – Get Free Investment Predictions
About Bafna Pharmaceuticals
Before deciding on Bafna Pharmaceuticals share price, it helps to understand the underlying business. Bafna Pharmaceuticals Ltd. manufactures pharmaceutical formulations, serving domestic and export markets.
Current-quarter and recent annual financial data for the company was not consistently available across public sources at the time of writing, with the most recently confirmed disclosures dating back several years, creating a very significant information gap given the stock’s dramatic price appreciation, more than tripling over the past year.
Bafna Pharmaceuticals Share Price Today: Key Levels
The table below summarises where Bafna Pharmaceuticals share price stands right now against its recent trading range and market value.
| Metric | Value |
|---|---|
| Bafna Pharmaceuticals CMP (NSE) | Rs 307.75 |
| Bafna Pharmaceuticals CMP (BSE) | Rs 308.55 |
| 52-Week High | Rs 318.50 |
| 52-Week Low | Rs 94.77 |
| Market Capitalisation | Approximately Rs 716 crore |
Bafna Pharmaceuticals share price is trading close to its 52-week high, having more than tripled from its 52-week low, despite very limited current financial disclosure being available.
Check the Univest Screener for Live Stock Data
Bafna Pharmaceuticals Financial Performance
The Bafna Pharmaceuticals share price trend is closely tied to how these numbers evolve each quarter. Current-quarter and recent annual financial data for Bafna Pharmaceuticals was not consistently available across public sources at the time of writing, with the most recently confirmed disclosures dating back several years.
Given this very significant data gap, particularly set against the stock’s dramatic price appreciation over the past year, investors should seek the company’s most recent exchange filings directly before drawing any conclusions about current profitability or growth trends.
| Period | Revenue | Net Profit | Comment |
|---|---|---|---|
| Most recent confirmed data | Not consistently available | Not consistently available | Significant gap relative to the current dramatic price move |
Valuation Check: Is Bafna Pharmaceuticals Share Price Expensive?
Any view on Bafna Pharmaceuticals share price should start from these valuation multiples. Bafna Pharmaceuticals share price currently reflects a price to earnings ratio of about 91.95 times trailing earnings, a significant premium to the broader pharmaceutical sector average of roughly 50.8 times based on available data, though this figure should be treated with real caution given the significant gap in current financial disclosure.
The price to book ratio stands near 7.4 times. Debt to equity of 0.39 is moderate. Given the very significant data limitations relative to the dramatic price appreciation, standard valuation comparisons carry limited reliability here.
Technical Signals: What the Chart Shows
Price action here often foreshadows the next move in Bafna Pharmaceuticals share price. Bafna Pharmaceuticals share price is up nearly 2 percent today, positioned close to its 52-week high of Rs 318.50, more than triple its 52-week low of Rs 94.77, reflecting a very dramatic price move over the past year. Given the significant data gaps around current financials, technical signals should be read with particular caution, as such a large price move without corresponding recent financial confirmation deserves close scrutiny.
Trading volumes remain light, so investors should seek the company’s most recent exchange filings for confirmation of the fundamentals behind this price move before relying on price action alone.
Download the Univest iOS App or Univest Android App to track Bafna Pharmaceuticals’ live price and technical levels.
Shareholding Pattern
Shifts here can influence Bafna Pharmaceuticals share price more than headline news on some sessions. Bafna Pharmaceuticals is a promoter-led pharmaceutical formulations manufacturer that has seen a dramatic stock price re-rating with limited current public disclosure to confirm the underlying reasons. A detailed current promoter, FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company’s latest exchange filing.
Why Investors Are Watching Bafna Pharmaceuticals
- Very strong recent stock price momentum: The stock has more than tripled from its 52-week low, reflecting significant investor interest, though the underlying financial confirmation for this move was not consistently available.
- Established pharmaceutical formulations operations: The company’s existing pharmaceutical manufacturing capacity provides an operational base.
Risks and Factors to Watch
- Very significant data limitations relative to the price move: Current-quarter and recent annual financial data was not consistently available across public sources at the time of writing, creating a substantial information gap given the stock’s dramatic appreciation.
- Dramatic price move without recent financial confirmation: A stock that has more than tripled without correspondingly current, verifiable financial disclosure deserves particular scrutiny before any investment decision.
- Pharmaceutical formulations competitive market: Bafna Pharmaceuticals competes against numerous domestic and international pharmaceutical formulations manufacturers.
- Small-cap liquidity risk: As a smaller-cap stock, trading liquidity can be more limited, which can amplify price volatility.
Bafna Pharmaceuticals Share Price Target: What the Data Suggests
Until then, Bafna Pharmaceuticals share price remains best tracked through live, verified data rather than a single fixed number. Given Bafna Pharmaceuticals’ very significant data limitations relative to its dramatic price appreciation, no reliable analyst price target framework applies to this stock at this time.
Investors considering this stock should seek the company’s most recent exchange filings directly to understand the fundamentals behind the price move, and should consult a SEBI-registered investment adviser given the data limitations involved.
Bafna Pharmaceuticals: Should You Buy, Hold, or Sell Right Now?
This is the core question behind Bafna Pharmaceuticals share price right now. The Bafna Pharmaceuticals buy or sell decision should account for the very significant gap between the dramatic price move and available financial disclosure.
The case for buying: Only investors who have independently sourced current company filings confirming the fundamentals behind the price appreciation may consider a position.
The case for holding: Existing shareholders who already have visibility into more current company information may choose to continue holding.
The case for avoiding: Most investors, particularly those wary of a dramatic price move without corresponding current, verifiable financial disclosure, would reasonably prefer to avoid this stock until more information becomes available.
Given the substantial data limitations here, consult a SEBI-registered investment adviser before proceeding.
Conclusion
Bafna Pharmaceuticals share price has more than tripled over the past year to trade near its 52-week high, even as current-quarter and recent annual financial data was not consistently available across public sources. This significant gap between price action and confirmed fundamentals calls for particular caution. This article is for informational purposes and not a personalised investment recommendation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Q1. Is Bafna Pharmaceuticals a good stock to buy right now?
Ans. Bafna Pharmaceuticals share price has more than tripled over the past year, but current-quarter and recent annual financial data was not consistently available across public sources at the time of writing. This significant data gap calls for particular caution before any investment decision.
Q2. Why has Bafna Pharmaceuticals’ share price risen so much?
Ans. Bafna Pharmaceuticals share price has more than tripled from its 52-week low over the past year, though the specific fundamental reasons for this move could not be confirmed from consistently available current financial disclosures at the time of writing.
Q3. What is the Bafna Pharmaceuticals share price today?
Ans. Bafna Pharmaceuticals share price is trading around Rs 308 on the NSE, close to its 52-week high of Rs 318.50. The stock’s 52-week low is Rs 94.77.
Q4. What is the Bafna Pharmaceuticals share price target?
Ans. Given Bafna Pharmaceuticals’ very significant data limitations relative to its dramatic price appreciation, no reliable analyst price target framework applies to this stock at this time.
Q5. What does Bafna Pharmaceuticals manufacture?
Ans. Bafna Pharmaceuticals manufactures pharmaceutical formulations, serving domestic and export markets.
Q6. What is Bafna Pharmaceuticals’ market capitalisation?
Ans. Bafna Pharmaceuticals has a market capitalisation of approximately Rs 716 crore.